Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherko Kuemmel

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
JAMA Oncology|September 25, 2025
600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical TrialFatima Cardoso, William Jacot, Sherko Kuemmel, et al.
Molecular Oncology|April 14, 2023
Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapyMattea Reinisch, Simona Bruzas, Oleg Gluz, et al.
BMC Cancer|May 24, 2024
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancerSherko Kuemmel, Catherine Harper-Wynne, Yeon Hee Park, et al.
NPJ Breast Cancer|March 30, 2022
Gene signatures in patients with early breast cancer and relapse despite pathologic complete responseSimona Bruzas, Oleg Gluz, Nadia Harbeck, et al.
Frontiers in Oncology|May 3, 2024
App-based support for breast cancer patients to reduce psychological distress during therapy and survivorship - a multicentric randomized controlled trialJosefine Wolff, Svenja Seidel, Pia Wuelfing, et al.
BMC Cancer|August 27, 2018
RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trialJoerg Heil, Peter Sinn, Hannah Richter, et al.
Breast Cancer Research and Treatment|March 22, 2021
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety studySherko Kuemmel, Carlo A Tondini, Jacinta Abraham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Breast Cancer Research : BCR|September 2, 2022
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trialCornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, et al.
Cancer|August 12, 2020
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancerMatthias Christgen, Oleg Gluz, Nadia Harbeck, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
JAMA Oncology|September 25, 2025
600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical TrialFatima Cardoso, William Jacot, Sherko Kuemmel, et al.
Molecular Oncology|April 14, 2023
Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapyMattea Reinisch, Simona Bruzas, Oleg Gluz, et al.
BMC Cancer|May 24, 2024
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancerSherko Kuemmel, Catherine Harper-Wynne, Yeon Hee Park, et al.
NPJ Breast Cancer|March 30, 2022
Gene signatures in patients with early breast cancer and relapse despite pathologic complete responseSimona Bruzas, Oleg Gluz, Nadia Harbeck, et al.
Frontiers in Oncology|May 3, 2024
App-based support for breast cancer patients to reduce psychological distress during therapy and survivorship - a multicentric randomized controlled trialJosefine Wolff, Svenja Seidel, Pia Wuelfing, et al.
BMC Cancer|August 27, 2018
RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trialJoerg Heil, Peter Sinn, Hannah Richter, et al.
Breast Cancer Research and Treatment|March 22, 2021
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety studySherko Kuemmel, Carlo A Tondini, Jacinta Abraham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Breast Cancer Research : BCR|September 2, 2022
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trialCornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, et al.
Cancer|August 12, 2020
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancerMatthias Christgen, Oleg Gluz, Nadia Harbeck, et al.
Pageof 9